EDITORIAL

Drug-eluting stents in the superficial femoral artery: seeing is believing

EuroIntervention 2016;12:1443-1445. DOI: 10.4244/EIJV12I12A238

John R. Laird
John R. Laird1*, MD; Melissa N. Loja2, MD, MAS
1. Division of Cardiovascular Medicine, The Vascular Center, University of California, Davis Medical Center, Sacramento, CA, USA; 2. Division of Vascular Surgery, The Vascular Center, University of California, Davis Medical Center, Sacramento, CA, USA


Antiproliferative drugs have revolutionised the management of coronary artery disease. Following implantation of the first drug-eluting stent (DES) in a coronary artery in 19991 and subsequent publication of the Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization (RAVEL) trial, the field of interventional cardiology was changed forever. The RAVEL trial demonstrated that a sirolimus-eluting stent dramatically reduced restenosis, major adverse cardiac events and mortality compared to a bare metal stent (BMS), with durable results up to five years2-4. Subsequent large-scale randomised trials confirmed these results, as well as the cost-effectiveness of both sirolimus- and ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Peripheral interventionsIliac / Femoral / PoplitealStents, devices and techniques
Read next article
Building the future together

Latest news